Disclosures for "Examining the Impact of Comorbid Depression on Healthcare Utilization, Cost, and Outcomes in Patients with Newly Diagnosed Epilepsy in the US"
-
Dr. Terman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xenon Pharmaceuticals. Dr. Terman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Terman has received research support from American Epilepsy Society. Dr. Terman has received research support from Epilepsy Study Consortium. Dr. Terman has received research support from New York University. The institution of Dr. Terman has received research support from NIH/NIA. Dr. Terman has received personal compensation in the range of $100,000-$499,999 for serving as a clinician scientist trainee for Susan S Spencer award with American Academy of Neurology.
-
Dr. Ong has received personal compensation for serving as an employee of Xenon Pharmaceuticals. Dr. Ong has stock in Xenon Pharmaceuticals.
-
Dr. Davis has nothing to disclose.
-
Mr. Yu has received personal compensation for serving as an employee of Inovalon.
-
Mr. Huang has received personal compensation for serving as an employee of Inovalon.
-
An immediate family member of Dr. Park has received personal compensation for serving as an employee of Regeneron. An immediate family member of Dr. Park has stock in Regeneron.
-
Mr. Thornton has received personal compensation for serving as an employee of Xenon Pharmaceuticals. Mr. Thornton has stock in Xenon Pharmaceuticals.